Inflammatory markers in juvenile arthritis and disease activity
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study looks at how certain blood markers relate to disease activity in children with juvenile idiopathic arthritis (JIA). It aims to help doctors better understand and track the condition, which could lead to improved care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 16 years old.
- You have been diagnosed with juvenile idiopathic arthritis (JIA) for at least 6 months.
- Your type of JIA is not systemic JIA (a form that affects the whole body).
- You do not have other autoimmune diseases, blood disorders, or active infections.
- You or your parent/guardian can give permission to join the study, and you can answer questions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at specific white blood cells (lymphocytes) in people with juvenile idiopathic arthritis (JIA) whose disease is inactive. It aims to understand how these cells differ based on the type of JIA and the medications used.
This study looks at children with arthritis to better understand their condition using clinical exams, lab tests, and ultrasounds. It may help doctors learn more about different types of juvenile arthritis.
This study creates a personalized medicine network to better understand and treat childhood arthritis. If you have JIA or unexplained joint inflammation, researchers will look at your biology to find the best treatment approach for you.
This study follows children and young adults newly diagnosed with certain types of arthritis or related conditions to learn more about their health over time. It may help doctors better understand how these diseases progress and how treatments work.
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
This study looks at blood (and related) markers that may reflect inflammation in people with juvenile idiopathic arthritis. It may help doctors better understand disease activity and guide future care for patients who are able to join.
Hear when a new Juvenile Idiopathic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.